Ms. Min-ran Li, The First Affiliated Hospital of Jinan University, China
Dr. Minran Li is the Chief Physician at the Division of Infectious Disease at The First Affiliated Hospital of Jinan University. He earned his M.D. in Internal Medicine from Peking University and has extensive expertise in infectious diseases, particularly nonalcoholic steatohepatitis (NASH) and chronic hepatitis B. His research focuses on discovering noninvasive biomarkers and the molecular mechanisms behind liver diseases. Dr. Li has published numerous articles and has been recognized as a Guangdong High-Level Personnel of Young Talents. š„š
Publication Profile
Scopus
Education
Ms. Li holds an M.D. in Internal Medicine (Infectious Disease) from Beijing Peking University, a Master’s in Internal Medicine from Hebei Medical University, and a Bachelor’s in Clinical Medicine. This strong educational foundation has empowered her expertise in infectious diseases, particularly liver-related conditions like NASH (nonalcoholic steatohepatitis) and CHB (chronic hepatitis B).
Work Experience
Currently serving as Chief Physician in the Division of Infectious Diseases at the First Affiliated Hospital of Jinan University, Ms. Li has progressively taken on roles of increasing responsibility, including as Associate Chief Physician at The Fifth Hospital of Shijiazhuang. Her work centers on managing liver diseases and exploring innovative biomarkers.
Research Interests
Her research focuses on discovering noninvasive biomarkers for pathological features of NASH in combination with CHB. Her findings on the role of HIGD1A and fibrosis development in liver disease have been pivotal in identifying therapeutic targets, advancing the understanding of liver disease progression.
Awards and Recognitions
Her dedication has been recognized with honors such as the Guangdong High-Level Personnel of Young Talents Program and the Yangcheng Good Doctor Award, underscoring her excellence in medical research and practice.
Conclusion
Ms. Min-ran Li’s strong academic background, leadership in liver disease research, and national and international recognition make her a strong candidate for the Research for Women Researcher Award.
Publication Top Notes
- Pan, Y. et al. (2024). Overexpression of LAG-3: a potential indicator of low immune function in tuberculosis. Frontiers in Cellular and Infection Microbiology, 14, 1410015. š¦ (0 citations)
- Li, M.-R. et al. (2024). The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B. Scandinavian Journal of Gastroenterology, 59(4), 445ā455. š„ (0 citations)
- Li, J.-Z. et al. (2023). Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis. Molecules, 28(23), 7936. šæ (0 citations)
- Li, M.-R. et al. (2023). Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population. Obesity Facts, 16(5), 427ā434. š (1 citation)
- Pan, Y. et al. (2023). Immune checkpoint inhibitors in cancer patients with COVID-19. Open Life Sciences, 18(1), 20220641. š (1 citation)
- Li, J.-Z. et al. (2022). Characteristics and treatment strategies for hepatocellular carcinoma caused by nonalcoholic fatty liver disease. Zhonghua gan zang bing za zhi, 30(12), 1392ā1396. š„ (0 citations)
- Yang, L. et al. (2022). Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. World Chinese Journal of Digestology, 30(16), 735ā742. š§¬ (1 citation)
- Li, J.-Z. et al. (2021). The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD. Virus Research, 298, 198405. š¬ (20 citations)
- Zheng, X.-L. et al. (2021). Effect of optimizing oxygen therapy on multiple organ function and prognosis of patients with COVID-19. Chinese Journal of Pathophysiology, 37(5), 909ā914. š« (0 citations)
- Li, M.-R. et al. (2020). Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. Journal of Viral Hepatitis, 27(10), 1044ā1051. š¦ (4 citations)